There is clearly something wrong with pharmaceutical innovation.
Antibiotic-resistant infections sicken more than two million Americans every year and kill at least 23,000. The World Health Organization has warned that a “post-antibiotic era” may be upon us, when “common infections and minor injuries can kill.” Even the world’s tycoons consider the proliferation of antibiotic-resistant bacteria one of the crucial global risks of our times, according to a survey by the World Economic Forum.
Yet the enthusiasm of the pharmaceutical industry for developing drugs to combat such a potential disaster might be best characterized as a big collective “meh.”
And this is hardly the drug industry’s only problem. Antibiotics, Professor Kinch told me, “are the canary in the coal mine.”
Read more . . .
The Latest on: Pharmaceutical innovation
[google_news title=”” keyword=”Pharmaceutical innovation” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pharmaceutical innovation
- Pharmaceuticals and Bangladeshon April 27, 2024 at 6:42 am
Learn more about why Bangladesh's pharma is drawing international investment. #Ad paid and presented by Beacon Pharmaceuticals PLC ...
- Bangladesh's burgeoning pharmaceuticalson April 27, 2024 at 6:09 am
Innovation, R&D and modern technology is changing the shape of Bangladesh’s pharmaceutical industry. Read more. #Ad Paid and presented by Beacon Pharmaceuticals PLC ...
- 1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep Onon April 27, 2024 at 2:15 am
One of the hottest areas in the pharmaceutical space right now is weight loss. Glucagon-like peptide-1 (GLP-1) medications such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound have become staples ...
- Eli Lilly’s acquisition of Nexus facility marks a new era for Pleasant Prairie’s pharmaceutical landscapeon April 26, 2024 at 9:37 am
Eli Lilly and Company has acquired a state-of-the-art injectable medicine manufacturing facility from Nexus Pharmaceuticals LLC. The acquisition of this FDA-approved facility in Pleasant Prairie ...
- Global Pharmaceutical Dissolution Testing Services Industryon April 26, 2024 at 6:22 am
Global Pharmaceutical Dissolution Testing Services Industry value of US$ 693.12 Million in 2023, by registering a CAGR of 8.3% By 2033 ...
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcripton April 26, 2024 at 5:49 am
BioMarin Pharmaceutical Inc. beats earnings expectations ... the results from our strategic assessment by Marin’s R&D portfolio. As innovation is fueled BioMarin’s success to date, we undertook a ...
- Rebounding R&D returns spell success for local pharmaceutical companies, report showson April 26, 2024 at 2:33 am
Investments in drug research and development are paying dividends while the cost to do so stays flat, a trend that appears to be benefitting local firms.
- The UAE is the obvious choice for a pharma manufacturing hubon April 25, 2024 at 7:07 am
Sector by sector, the UAE government is supporting these changes, advising on ways forward and guiding startups and incumbents alike through economic quakes and torrents. A major focus of the ...
- Deloitte's 14th Annual Pharmaceutical Innovation Report: Pharma R&D Return on Investment Rebounds After Record Lowon April 25, 2024 at 4:03 am
Projected return on investment in pharma research and development (R&D) in 2023 has risen to 4.1%, climbing back from 2022's record low of 1.2%. The leading 20 global pharmaceutical companies ...
- Europe falling behind US and China in pharma innovation, warns AstraZeneca chiefon April 25, 2024 at 3:53 am
Europe is “falling behind” the US and China in life sciences innovation, the chief executive of AstraZeneca has said, warning that one of the continent’s leading industries needs to spend more on ...
via Bing News
